Alkermes plc (ETR:8AK)
Germany · Delayed Price · Currency is EUR | Market Cap | 6.21B +42.2% |
| Revenue (ttm) | 1.46B +10.8% |
| Net Income | 57.88M -81.0% |
| EPS | 0.34 -81.3% |
| Shares Out | n/a |
| PE Ratio | 107.34 |
| Forward PE | 26.54 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 37.02 |
| Previous Close | 37.73 |
| Day's Range | 37.02 - 37.52 |
| 52-Week Range | 35.34 - 48.28 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Oct 29, 2026 |
About Alkermes
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramu... [Read more]
Financial Performance
In 2025, Alkermes's revenue was $1.48 billion, a decrease of -5.25% compared to the previous year's $1.56 billion. Earnings were $241.66 million, a decrease of -34.16%.
Financial numbers in USD Financial StatementsNews
Alkermes resumed with a Neutral at Goldman Sachs
Goldman Sachs resumed coverage of Alkermes (ALKS) with a Neutral rating and $50 price target Goldman resumed coverage of the biotechnology sector, saying the group has continued to outperform despite…
Alkermes price target raised to $61 from $58 at Baird
Baird raised the firm’s price target on Alkermes (ALKS) to $61 from $58 and keeps an Outperform rating on the shares following “impressive” OX2R proof-of-concept data in ADHD. Published first…
Alkermes data show measurable improvements in ADHD, says H.C. Wainwright
H.C. Wainwright keeps a Neutral rating on Alkermes (ALKS) after the company reported the first clinical evidence of an orexin-2 receptor agonist producing measurable improvements in attention-deficit/...
Alkermes jumps 8% to $46.99 after Phase I adult ADHD data
07:46 EDT Alkermes (ALKS) jumps 8% to $46.99 after Phase I adult ADHD data
Alkermes announces Phase 1b results of ALKS 7290 in ADHD
Alkermes (ALKS) announced topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor agonist in development for the treatment of...
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company's novel, investigational orexin 2 ...
Alkermes announces appointment of Whitaker to Board of Directors
Alkermes (ALKS) announced the appointment of a new independent director, Anne Whitaker, to the company’s Board of Directors. Whitaker most recently served as chief executive officer of Aerami Therapeu...
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company's Board of Directors (the Board). Ms. Whitaker is a...
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now ...
Mizuho survey shows no consensus into Alkermes ADHD data
Mizuho conducted a survey of 13 investors ahead of Alkermes (ALKS)’ Phase 1b trial of ALKS-7290 in adult attention-deficit/hyperactivity disorder, which is expected this month. Expectations into the d...
Alkermes’ alixorexton featured in published Phase 2 study of narcolepsy
Alkermes (ALKS) announced the publication of data from the Vibrance-1 phase 2 study of alixorexton in adults with narcolepsy type 1, or NT1, in The Lancet Neurology. Alixorexton is a…
The Lancet Neurology Publishes Data From Alkermes' Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the publication of data from the Vibrance‑1 phase 2 study of alixorexton in adults with narcolepsy type 1 (NT1) in The Lancet Neuro...
Alkermes price target raised to $61 from $60 at JPMorgan
JPMorgan raised the firm’s price target on Alkermes (ALKS) to $61 from $60 and keeps a Neutral rating on the shares.
Alkermes price target raised to $58 from $48 at Baird
Baird raised the firm’s price target on Alkermes (ALKS) to $58 from $48 and keeps an Outperform rating on the shares. The firm updated its model following Q2 results and…
Alkermes sinks 5% to $50.05 following Q2 report
08:45 EDT Alkermes (ALKS) sinks 5% to $50.05 following Q2 report
Alkermes Earnings Call Transcript: Q2 2026
Q2 2026 saw strong revenue growth, driven by proprietary products and the successful integration of LUMRYZ. The orexin pipeline advanced with positive clinical data, while commercial execution and expanded access for key brands support long-term growth.
Alkermes Earnings release: Q2 2026
Alkermes released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Alkermes Slides: Q2 2026
Alkermes has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on July 28, 2026.
Alkermes Quarterly report: Q2 2026
Alkermes has published its Q2 2026 quarterly earnings report on July 28, 2026.
Alkermes reaffirms FY26 revenue view $1.73B-$1.84B, consensus $1.81B
Sees adjusted EBITDA $370M-$410M
Alkermes reports Q2 revenue $496.0M, consensus $457.36M
Reports GAAP EPS 0c vs. 52c last year. The company said, “As we move into the second half of the year, we have clear priorities and a sharp focus on…
Alkermes reports Q2 EPS 0c, consensus 29c
Reports Q2 revenue $496M, consensus $457.36M. “As we move into the second half of the year, we have clear priorities and a sharp focus on execution. With our first ADHD…
Alkermes says Blair Jackson to assume CEO role on August 1
“The second quarter was marked by strong commercial performance and meaningful progress across our pipeline as we continued to execute on our strategic priorities. Our commercial portfolio consists of...
Alkermes price target raised to $65 from $43 at Piper Sandler
Piper Sandler analyst David Amsellem raised the firm’s price target on Alkermes (ALKS) to $65 from $43 and keeps an Overweight rating on the shares. With Alkermes’ shares up 88%…
Alkermes plc Reports Second Quarter 2026 Financial Results
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today reported financial results for the quarter ended June 30, 2026. To view the detailed second quarter 2026 earnings press release and presentat...